Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intramuscular ziprasidone mesylate
Intramuscular ziprasidone · 1 trial · 1 indication
BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline.
| Arm | Type | Description |
|---|---|---|
| Intramuscular ziprasidone | EXPERIMENTAL | - |
| Intramuscular haloperidol | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Intramuscular ziprasidone mesylate | DRUG | The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days. |
| Intramuscular haloperidol | DRUG | The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days. |
Inclusion Criteria: * Male or female Chinese subjects aged 18-65 years (including 65) at screening. * Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X). * Subjects who are in acute phase of schizophrenia and are appropriate to receive...
Top 15 of 16 competitors
Intramuscular ziprasidone is an injectable small molecule developed by Pfizer, Inc. (NYSE: PFE) for schizophrenia. It is given by intramuscular injection and has been studied in a Phase 3 trial in patients with agitation. It is also known as intramuscular ziprasidone mesylate.
Intramuscular ziprasidone is used for schizophrenia, specifically in patients with agitation. Its clinical development has focused on this psychiatric indication, and the completed Phase 3 study enrolled adults 18 years and older with schizophrenia in China.
Intramuscular ziprasidone is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 3 clinical trial evaluating the drug in patients with schizophrenia and agitation.
Intramuscular ziprasidone is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was a randomized, open-label, active-controlled, multicenter trial conducted in China.
Intramuscular ziprasidone has been studied in one completed Phase 3 trial, NCT00723606. Titled a randomized, open-label, multi-center study to evaluate the efficacy and safety of intramuscular ziprasidone in patients with agitation, it enrolled 376 participants with schizophrenia in China.
Yes. Intramuscular ziprasidone mesylate is an alternative name for intramuscular ziprasidone. Both names refer to the same Pfizer small molecule developed for schizophrenia, and the Phase 3 trial NCT00723606 evaluated it in patients with agitation.